You are using an older browser version. Please use a supported version for the best MSN experience.

Aurobindo Pharma gets nod to market mental illness drug in US

LiveMint logoLiveMint 03-06-2014 PTI

New Delhi: Aurobindo Pharma Ltd has received the US health regulator’s approval to market a generic version of AbbVie Inc.’s Depakote ER extended-release tablets, used for treating mental illness, in the US market.

The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Divalproex Sodium extended-release tablets in strengths of 250mg and 500mg, Aurobindo Pharma said in a statement on Tuesday. The Hyderabad-based firm said the “product is ready for launch”.

Divalproex Sodium extended-release tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features.

As per IMS sales data, the product had a market size of around $690 million for the 12 months ended March 2014. The company said the product has been approved out of its unit VII formulation facility in Hyderabad. It now has a total of 194 abbreviated new drug application approvals from USFDA. Aurobindo shares were trading at `626.95 apiece on the BSE, down 1.93% from its previous close.

More From LiveMint

image beaconimage beaconimage beacon